Dr. Parul Thakral

Senior Director

24 years of experience

Nuclear Medicine

BSc, MSc, PHD

Fortis Memorial Research Institute (FMRI), Gurgaon

English, Hindi

Consultation Fee ₹ 1500

Book an Appointment

About Dr. Parul Thakral

Dr. Parul Thakral is a renowned Nuclear Medicine Expert in India, practicing for more than 24 years.
Her expertise includes conjugation & standardization of Radiolabeling and quality control of Ant-CD20 Monoclonal Antibody Rituximab with various radionuclides (90-Yttrium, 68-Gallium, 177-Lutetium).
She also has extensive experience with diverse Radionuclides & Radiopharmaceuticals.
She did her B.Sc. in Medical Technology (Radiography) in 2000 and an M.Sc. in Nuclear Medicine Technology in 2006 from All India Institute of Medical Sciences.
She also holds a Ph.D. in Radiochemistry & Clinical Nuclear Medicine from AIIMS, a renowned institute in Asia, in 2013.
Dr. Thakral is an active member of the World Association of Radiopharmaceutical & Molecular Therapy, the European Association of Nuclear Medicine (EANM), and the Society of Nuclear Medicine - India.

Education

Bsc, All India Institute of Medical Sciences, New Delhi, 2000
MSc, All India Institute of Medical Sciences, New Delhi, 2006
PhD, ( Nuclear medicine) All India Institute of Medical Sciences, New Delhi,2013

Training & Certificates

Assessment of Therapeutic Response to Yttrium-90 Radiolabelled Chimeric Anti-CD20 Antibody – Rituximab in patients of Relapsed and Refractory B-Cell Non-Hodgkin’s Lymphoma.
Study of Changes in Sleep Architecture, Melatonin Levels & Metabolic Abnormalities on F-18 Flurodeoxyglucose Positron Emission Tomography (FDG-PET) in person with Mild Cognitive Impairment (MCI) progressing to Alzheimer's Type Dementia (AD).

Past Experience

Senior Research Fellow, Department of Nuclear Medicine, AIIMS, New Delhi, 2016
RSO-II & Senior Nuclear Medicine Technologist, Sir Ganga Ram Hospital, 2009

Awards

First prize in the 3rd International Medical Olympiad for Contribution in Radioimmunotherapy in Oncology.

Associations/Membership

World Association of Radiopharmaceutical & Molecular Therapy
European Association of Nuclear Medicine (EANM)
Society of Nuclear Medicine - India

Paper Published

An approach for conjugation of 177Lu- DOTA-SCN- Rituximab (BioSim) and its evaluation for radioimmunotherapy of relapsed and refractory B-cell Non Hodgkins Lymphoma patients
Feasibility of 18F-FDG Labelling of Leucocytes in a Centre Without an On-Site Cyclotron and Monitoring of Radiation Dose to Occupational Worker in the Labelling Procedure
Dosimetric analyses of Kidneys, Liver, Spleen, Pituitary gland and Neuroendocrine tumors of patients treated with 177Lu-DOTATATE
In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma
Preliminary experience with Yttrium-90-labelled Rituximab (chimeric anti CD-20 antibody) in patients with relapsed and refractory B cell NHL
Radiation Dose to the Occupational Worker during the Synthesis of 188Re-labeled Radiopharmaceuticals in the Nuclear Medicine Department
Radiation Exposure to the Nuclear Medicine Personnel During Preparation and Handling of 213Bi-Radiopharmaceuticals
Charting the Course of Targeted ? Therapy With First-in-Human, Postadministration Image-Guided Dosimetry and Response Assessment of 212Pb-VMT-?-NET in Metastatic Neuroendocrine Tumors\
The Role of PET-CT-Guided Metabolic Biopsies in Improving Yield of Inconclusive Anatomical Biopsies: A Review of 5 Years in a Teaching Hospital
Validation of In-House Kit-Like Synthesis of 68Ga-Trivehexin and Its Biodistribution for Targeting the Integrin ?v?6 Expressing Tumors
Upfront Use of 177Lu-Labeled PSMA Radioligand Therapy and Treatment Response Assessment in Treatment-Naive Prostate Cancer
Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease
Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy
Incremental Value of Ga-68 Prostate-Specific Membrane Antigen-11 Positron-Emission Tomography/Computed Tomography Scan for Preoperative Risk Stratification of Prostate Cancer
In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma
Molecular Imaging to the Surgeons Rescue: Gallium-68 DOTA-Exendin-4 Positron Emission Tomography-Computed Tomography in Pre-operative Localization of Insulinomas
Radiation Exposure to the Nuclear Medicine Personnel During Preparation and Handling of 213Bi-Radiopharmaceuticals
Dosimetric analysis of patients with gastro-entero-pancreatic neuro endocrine tumors (NETs) treated with PRCRT (Peptide Receptor Chemo Radionuclide Therapy) using Lu-177 DOTATATE and Capecitabine/Temozolamide (CAP/TEM)
Radiation Dose to the Occupational Worker during the Synthesis of Re-labeled Radiopharmaceuticals in the Nuclear Medicine Department
Rare sites of metastases in prostate cancer detected on Ga-68 PSMA PET/CT scan-a case series